

13 May 2025

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

AGM Correction

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it is writing to Shareholders to explain that the Company's recent Notice of Annual General Meeting (the "Notice") contained a manifest clerical error.

This clerical error relates only to Resolutions 6 and 7, which, in the case of Resolution 6, concerns the authority sought by the Directors to allot shares in the Company and, in the case of Resolution 7, the disapplication of pre-emption rights.

The resolutions as printed in the Notice include a quite obviously incorrect number for the nominal value of the shares to which the proposed authorities would apply (the number mistakenly used was the number of shares in issue rather than their nominal value). Shareholders will note that the description of the authorities sought "*.... (representing approximately 100% of the nominal value of the issued ordinary share capital of the Company)....*" is quite obviously correct in the context.

This is purely an administrative oversight, and the intention was always for the authorities to be limited to the 100% of the Company's issued share capital as described. Directors apologise for any confusion this may have caused notwithstanding the intention of the extent of the authorities sought being clear from the description in each of the resolutions themselves.

Accordingly, the corrected resolutions, which will be presented at the Company's AGM, are as follows:

Corrected Resolution 6:

Directors' authority to allot shares

THAT, in accordance with section 551 of the Companies Act 2006 ("CA 2006"), the Directors be generally and unconditionally authorised to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company (the "Rights") up to an aggregate nominal amount of £40,935.39 (representing approximately 100% of the nominal value of the issued ordinary share capital of the Company) provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the commencement of the next Annual General Meeting of the Company or 29 August 2026, whichever is earlier to occur, save that the Company may, before such expiry, make offer(s) or enter agreement(s) which would or might require shares to be allotted or Rights to be granted after such expiry and the Directors may allot shares or grant Rights in pursuance of such offers or agreements notwithstanding that the authority conferred by this resolution has expired; and all unexercised authorities previously granted to the Directors to allot shares and grant Rights be and are hereby revoked.

Corrected Resolution 7:

Disapplication of pre-emption rights

THAT, conditional on the passing of Resolution 6 above, and in accordance with section 570 of the CA 2006, the Directors be generally empowered to allot equity securities (as defined in section 560 of the CA 2006) for cash pursuant to the authority conferred by Resolution 6 or by way of a sale of treasury shares, as if section 561(1) of the CA 2006 did not apply to any such allotment, provided that this power shall be limited to:

(a) the allotment of equity securities in connection with an offer of equity securities to the holders of ordinary shares in proportion (as nearly as may be practicable) to their respective holdings; and to holders of other equity securities as required by the rights of those securities or as the Directors otherwise consider necessary, but

subject to such exclusions or arrangements as the Directors may deem necessary or expedient in relation to the treasury shares, fractional entitlements, record dates, arising out of any legal or practical problems under the laws of any overseas territory or the requirements of any regulatory body or stock exchange; and

(b) the allotment of equity securities (otherwise than pursuant to sub paragraph (a) above) up to an aggregate nominal amount of £40,935.39 (representing approximately 100% of the nominal value of the issued ordinary share capital of the Company); and provided that this power shall expire on the commencement of the next Annual General Meeting of the Company or 29 August 2026, whichever is earlier to occur (unless renewed, varied or revoked by the Company prior to or on that date) save that the Company may, before such expiry, make offer(s) or agreement(s) which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offers or agreements notwithstanding that the power conferred by this resolution has expired.

Explanatory Notes (repeated from the Notice)

For ease of reference, the Explanatory Notes relating to Resolutions 6 and 7 are repeated below in exactly the wording in the AGM Notice originally sent to Shareholders.

The Company is currently in the clinical trial stage for its lead product candidate HG-CT-1. Clinical development activities are inherently capital-intensive and lead to a significantly increased expenditure rate. In order to maintain strategic and operational flexibility, the Company must ensure it has access to timely and efficient financing options, including equity financing. Shareholders will be aware in general of the much increased level of costs incurred, arising from the preparation and conduct of clinical trials of HG-CT-1 and the fact that this will continue for a considerable amount of time.

While the Directors will continue to seek non-diluting funds, granting this authority at a higher than usual threshold enables the Company to respond swiftly to market opportunities and potential funding needs without delay or the expense of convening additional shareholder meetings, with the further delay and cost of doing so. This authority is therefore considered prudent and in the best interests of shareholders given the Company's stage of development and evolving capital requirements.

These corrections do not affect any of the other resolutions or any other information included in the AGM notice. All other aspects of the AGM, including the date, time, and venue, remain unchanged.

The AGM will take place, as scheduled, at 1.00 p.m. BST on Thursday 29 May 2025 at the offices of SP Angel Corporate Finance LLP, Prince Frederick House, 35-39 Maddox Street, London W1S 2PP.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Enquiries:

Hemogenyx Pharmaceuticals plc

<https://hemogenyx.com>

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAFFFFIEAIFLIE